Remove Article Remove Biosimilars Remove Drug Research
article thumbnail

Article EMA Thank You What will the orphan drug market exclusivity haircut mean for industry?

Agency IQ

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Other orphan drugs, which, by definition, address an unmet medical need, “only” receive 9 years of market exclusivity.

article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

(ACT EU) / Clinical Trials Coordination Groups (CTCG) 9/11/2024 9/11/2024 Public launch event on the guideline on good pharmacovigilance practices Module XVI on risk minimization measures and its Addendum II Webinar ( OPEN ) EMA 9/12/2024 9/12/2024 ENVI meeting Committee meeting ( OPEN ) Environment, Public Health and Food Safety (ENVI) 9/13/2024 9/13/2024 (..)